Stock Scorecard

Stock Summary for Citius Pharmaceuticals Inc (CTXR) - $0.19 as of 11/20/2024 3:56:18 PM EST

Total Score

13 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CTXR

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CTXR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CTXR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CTXR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CTXR (31 out of 90)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 2
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0

Latest News for for CTXR

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update 8/9/2024 11:30:00 AM
Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection - Citius Pharma ( NASDAQ:CTXR ) 8/8/2024 9:41:00 PM
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology - Citius Pharma ( NASDAQ:CTXR ) , TenX Keane ( NASDAQ:TENK ) 8/6/2024 1:49:00 PM
Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products - Citius Pharma ( NASDAQ:CTXR ) , TenX Keane ( NASDAQ:TENK ) 7/29/2024 3:12:00 PM
This Pharma Company Is Preparing To Launch Its Lead Candidate - Citius Pharma ( NASDAQ:CTXR ) 7/24/2024 12:15:00 PM
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates 7/10/2024 1:10:00 PM
Citius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream Infections - Citius Pharma ( NASDAQ:CTXR ) 5/21/2024 5:40:00 PM
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution 5/21/2024 11:00:00 AM
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update 5/14/2024 8:05:00 PM
All Stock Offering News and Press Releases from PR Newswire 5/3/2024 7:18:00 PM

Financial Details for CTXR

Company Overview
Ticker CTXR
Company Name Citius Pharmaceuticals Inc
Country USA
Description Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. The company is headquartered in Cranford, New Jersey.
Sector Name MANUFACTURING
Industry Name MOTOR VEHICLE PARTS & ACCESSORIES
Most Recent Quarter 6/30/2024
Next Earnings Date 12/27/2024

Stock Price History
Last Day Price 0.19
Price 4 Years Ago 1.02
Last Day Price Updated 11/20/2024 3:56:18 PM EST
Last Day Volume 3,914,274
Average Daily Volume 2,032,290
52-Week High 1.07
52-Week Low 0.16
Last Price to 52 Week Low 18.75%

Valuation Measures
Trailing PE N/A
Industry PE 18.91
Sector PE 38.01
5-Year Average PE -4.24
Free Cash Flow Ratio 1.90
Industry Free Cash Flow Ratio 20.34
Sector Free Cash Flow Ratio 48.04
Current Ratio Most Recent Quarter 6.75
Total Cash Per Share 0.10
Book Value Per Share Most Recent Quarter 0.47
Price to Book Ratio 0.43
Industry Price to Book Ratio 2.38
Sector Price to Book Ratio 4.56
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 1.05
Sector Price to Sales Ratio Twelve Trailing Months 2.42
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 2

Share Statistics
Total Shares Outstanding 180,725,000
Market Capitalization 34,337,750
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 3.26%
Reported EPS 12 Trailing Months -0.24
Reported EPS Past Year -0.17
Reported EPS Prior Year -0.23
Net Income Twelve Trailing Months -38,292,585
Net Income Past Year -32,542,912
Net Income Prior Year -33,640,646
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth -57.84%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet
Total Cash Most Recent Quarter 17,911,192
Total Cash Past Year 26,480,928
Total Cash Prior Year 41,711,690
Net Cash Position Most Recent Quarter 17,738,222
Net Cash Position Past Year 26,143,375
Long Term Debt Past Year 337,553
Long Term Debt Prior Year 337,553
Total Debt Most Recent Quarter 172,970
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 90,831,108
Total Stockholder Equity Prior Year 102,825,865
Total Stockholder Equity Most Recent Quarter 85,683,899

Free Cash Flow
Free Cash Flow Twelve Trailing Months -29,088,906
Free Cash Flow Per Share Twelve Trailing Months -0.16
Free Cash Flow Past Year -29,060,214
Free Cash Flow Prior Year 0

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.03
MACD Signal -0.02
20-Day Bollinger Lower Band 0.13
20-Day Bollinger Middle Band 0.54
20-Day Bollinger Upper Band 0.95
Beta 1.66
RSI 29.37
50-Day SMA 0.66
150-Day SMA 0.98
200-Day SMA 1.23

System
Modified 11/20/2024 10:29:26 PM EST